IBM Forum for Finance 2012

Smarter Analytics. Smarter Outcomes.



Marco Zevenboom VP Finance, Ferring Pharmaceuticals 26 April 2012


Ferring Pharmaceuticals

Corporate Performance Management

- An implementation experience -







Ferring Pharmaceuticals

From where did we start?

What did we try to accomplish?

The right approach for a global program

Outcomes & Results

Q&A



Ferring Pharmaceuticals at a glance



- Ferring was founded in Sweden in 1950 by Dr. Frederik
 Paulsen
- Headquarters: Saint-Prex, Switzerland
- Production sites in 9 countries: Germany, Switzerland, Denmark, Czech republic, Israel,
 Argentina, China, Mexico and Scotland
- R&D Centers in 7 countries: Denmark, Israel, USA, Switzerland, India, Japan and Scotland

■ **Employees**: 4'300

Locations: > 50 countries

Sales 2011: EUR 1'2 bio

Growth: Double-digit average annual growth rate over the last two decades



Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven pharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of female healthcare (infertility, obstetrics) urology, gastroenterology, endocrinology and osteoarthritis.

From its origins as a Scandinavian company, Ferring has developed into an global business with operating units in all important pharmaceutical markets around the world.







Ferring Pharmaceuticals


Ferring's marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ over 4300 people throughout the world, while treatments are available in more than 100 countries.

This geographical expansion as well as successfull lifecycle management has allowed Ferring to maintain a double digit annual growth rate over the last two decades.









Ferring Pharmaceuticals

From where did we start?

What did we try to accomplish?


The right approach for a global program

Outcomes & Results

Q&A




From where did we start



- •ER is no longer supported by the vendor
- CDM Analysis tools are outdated and lack functionality.
- ·Data entry and validation occurs too late and too error prone.
- · Budgeting and Forecasting are not efficiently supported
- ·Limited BI functionality with easy access and reporting for a large user community





Ferring Pharmaceuticals


From where did we start?

What did we try to accomplish?

The right approach for a global program

Outcomes & Results

Q&A





What did we try to accomplish?

(Finance)

- ✓ Replace ER (not supported in the future)
- ✓ Improve interface with source systems
- ✓ Improve budgeting and forecasting functionality
- ✓ Improve analysis & query functionality
- ✓ Improve reporting functionality
- ✓ Combine Financial Consolidation, Budgeting & Forecasting, Analysis & Reporting in one tool (based on cross functional datamodel)




What did we try to accomplish?

(Global Marketing)

CPM Project should provide GMO / commercial operations with:

- Reliable, robust, granular data
- A versatile, accessible tool (set of tools) allowing to perform various types of analysis, simulation, forecasting at all levels according to business needs, now and in the future, without a need to rebuild the system; and supporting seamless crossfunctional communication and cooperation





Ferring Pharmaceuticals

From where did we start?

What did we try to accomplish?

The right approach for a global program

Outcomes & Results

Q&A



Tool Selection (Q4 2007 / Q1 2008)

4 vendors shortlisted (RFP phase)

- Cognos (IBM)
- Business Objects (SAP)
- Hyperion (Oracle)
- Perf. Point Server (Microsoft)

2 vendors in proof-of-concept phase


- Cognos (IBM)
- Business Objects (SAP)

Cognos / IBM was selected

- Best overall coverage of functionality, service, price
- Less risk on application roadmap
- Best integration between modules.



Implementation partner selection & concept



Business & Decision (B&D) has been selected as the implementation partner We contracted B&D for the full implementation project and Cognos / IBM was (sub)contracted by B&D

- · Clear responsibilty
- Less risk of Ferring being in between 2 parties
- · Implementation team is key success factor



Business&Decision contribution

Phase	B&D Contribution
Project 0	Assistance in defining common structures
RFP for product selection	 Writing of the RFP Support in tool selection process
Scoping	 High-level business requirements gathering Definition of the architecture (first-day and long-term) Project quotation High-level planning for entire program
Phase 1: Financial Consolidation	 Project Management (including Ferring ressources and third parties) Detailed analysis Design Delivery Support & Maintenance
Phase 2: Planning	 Project Management (including Ferring ressources and third parties) Design Delivery Support & Maintenance
Phase 3: Business Intelligence	DesignDelivery



Ferring selected IBM - Cognos as main Software provider




Function	Package
Financial consolidaton	Cognos Controller
Planning	Cognos Planning
Business Intelligence	Cognos BI



The overall CPM project is split in 3 phases:

- Project zero: Define dimensional structure covering information needs in the future (2008)
- Phase I: Financial Consolidation & Reporting (live: Mar 2009)
- Phase II: Planning (live: Sep 2010)
- Phase III: BI & Global reporting (partially live)







Starting point for Project zero (= end product INS)








Event Item COPS









Business Partner

Period



Project Zero – the foundation

Objectives

 Recommend an efficient dimensional structure (business data model) for source systems and CPM


Recommend solution for efficient data validation before feeding CPM

Deliverables

Dimensional structure for data collection and the related dimension members and tree structure


Summary of relationship between dimensions

Recommendation of how to organise data validation






Solution & Data Flows







Ferring Pharmaceuticals

From where did we start?

What did we try to accomplish?

The right approach for a global program

Outcomes & Results

Q&A



Evaluation of result against objectives

(Finance)

Replace ER (not supported in the future)

Cognos is supported application through a solid partner (IBM)



Improve interface with source systems

Much better automation and validation through in-house developed tool (DIMA)



Improve budgeting and forecasting functionality So far limited improvements, Cognos Planning some inefficiencies (upgrading to Cognos 10)



Improve analysis & query functionality

→ Big improvement with Cognos BI (Query Studio)



Improve reporting functionality

Studio)



Combine Financial Consolidation. Budgeting & Forecasting, Analysis & Reporting in one tool (based on cross functional datamodel)

We have developed the cross functional datamodel (Project Zero), but the (technical) integration between the Cognos applications is not as smooth as expected

Big improvement with Cognos BI (Report



Evaluation of result against objectives (Global Marketing)

CPM Project should provide GMO / commercial operations with:

- Reliable, robust, granular data
- A versatile, accessible tool (set of tools)
 allowing to perform various types of analysis,
 simulation, forecasting at all levels according
 to business needs,

With Cognos BI there is a much better basis for this: sales by item, business unit, customer, legal entity and invoice currency accessible through Cognos BI application (Query studio, Report studio), but simulation functionality is not yet where it should be






Lessons learned

- Do not under estimate historical data migration effort when moving to new structures
- Put more emphasize in the proof-of-concept phase with the last 2 software candidates
- Rethink & simplify processes if historical ways of doing things lead to exceptions
- Don't try to be too detailed on user requirements as long as you don't know the tool to be used
- Selection of project team members ensure enough resources







Ferring Pharmaceuticals

From where did we start?

What did we try to accomplish?

The right approach for a global program

Outcomes & Results

Q&A

